Duchenne Muscular Dystrophy - Latest News and breaking headlines - Benzinga

Duchenne Muscular Dystrophy

Stealth BioTherapeutics Showcases New Nonclinical Data From Duchenne Muscular Dystrophy Program

Stealth BioTherapeutics Showcases New Nonclinical Data From Duchenne Muscular Dystrophy Program

FDA Issues Clinical Hold On Dyne's IND For Duchenne Muscular Dystrophy Program

FDA Issues Clinical Hold On Dyne's IND For Duchenne Muscular Dystrophy Program

Pfizer's Duchenne Gene Therapy Trial Put On FDA Hold After Patient Death

Pfizer's Duchenne Gene Therapy Trial Put On FDA Hold After Patient Death

FDA Issues Clinical Hold On Dyne's IND For Duchenne Muscular Dystrophy Program

FDA Issues Clinical Hold On Dyne's IND For Duchenne Muscular Dystrophy Program

Pfizer's Duchenne Gene Therapy Trial Put On FDA Hold After Patient Death

Pfizer's Duchenne Gene Therapy Trial Put On FDA Hold After Patient Death

Edgewise Therapeutics Posts Data From Early-Stage Muscle Wasting Disease Trial

Edgewise Therapeutics Posts Data From Early-Stage Muscle Wasting Disease Trial

Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements

Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements

Edgewise Therapeutics Posts Data From Early-Stage Muscle Wasting Disease Trial

Edgewise Therapeutics Posts Data From Early-Stage Muscle Wasting Disease Trial

Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements

Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements

Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program

Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program

Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%

Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%

Duchenne Muscular Dystrophy Recent News

Solid Biosciences Stock Gains After Duchenne Dystrophy Gene Therapy Data

Solid Biosciences Stock Gains After Duchenne Dystrophy Gene Therapy Data

Sarepta's Stock Trading Higher As Duchenne Muscular Dystrophy Gene Therapy Shows Promise In Open-Label Study

Sarepta's Stock Trading Higher As Duchenne Muscular Dystrophy Gene Therapy Shows Promise In Open-Label Study

Monthly Dosing Of Sarepta's Next-Gen Eteplirsen Can Potentially Achieve Over 10% Higher Dystrophin Expression In DMD Patients

Monthly Dosing Of Sarepta's Next-Gen Eteplirsen Can Potentially Achieve Over 10% Higher Dystrophin Expression In DMD Patients

Analysts: Roche Partnership Derisks Sarepta Investor Concerns

Analysts: Roche Partnership Derisks Sarepta Investor Concerns

Sarepta, Roche Strike Gene Therapy Licensing Agreement Worth Up To $2.85B

Sarepta, Roche Strike Gene Therapy Licensing Agreement Worth Up To $2.85B

Solid Biosciences Rips Higher On Positive Biomarker Data For DMD Drug

Solid Biosciences Rips Higher On Positive Biomarker Data For DMD Drug

FDA Approves Sarepta's Second DMD Drug, Analyst Projects $500M-Plus Opportunity

FDA Approves Sarepta's Second DMD Drug, Analyst Projects $500M-Plus Opportunity

Solid Biosciences Shares Crash To Record Low After FDA Places Gene Therapy Program On Hold

Solid Biosciences Shares Crash To Record Low After FDA Places Gene Therapy Program On Hold

Sarepta Plunges After FDA Spurns Its Second Duchenne Muscular Dystrophy Drug

Sarepta Plunges After FDA Spurns Its Second Duchenne Muscular Dystrophy Drug

PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients

PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients

Solid Biosciences Tanks After Reporting Adverse Event In Duchenne Muscular Dystrophy Trial

Solid Biosciences Tanks After Reporting Adverse Event In Duchenne Muscular Dystrophy Trial

Why Wave Life Sciences's Valuation Is Falling By 25% (NASDAQ:WVE)

Why Wave Life Sciences's Valuation Is Falling By 25% (NASDAQ:WVE)

Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress

Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress

Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations'

Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations'

Sarepta Hits Record High As Duchenne Muscular Dystrophy Gene Therapy Yields Positive Results In Early-Stage Study

Sarepta Hits Record High As Duchenne Muscular Dystrophy Gene Therapy Yields Positive Results In Early-Stage Study

Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics

Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics

Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy

Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy

Goldman Sachs Gets Firm On Solid Biosciences

Goldman Sachs Gets Firm On Solid Biosciences

Sarepta's Beat And Raise Streak Continues

Sarepta's Beat And Raise Streak Continues

U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'

U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'

Sarepta Marks A 'Very Important Day' For The DMD Community

Sarepta Marks A 'Very Important Day' For The DMD Community

Down 16% Over May, Has Sarepta Become A Cheap Takeout Target?

Down 16% Over May, Has Sarepta Become A Cheap Takeout Target?

Exclusive: Capricor CEO Talks Exondys Competition

Exclusive: Capricor CEO Talks Exondys Competition